NCT06457074

Finerenone for Patients With Primary Aldosteronism (FAIRY)

Finerenone for Patients With Primary Aldosteronism (FAIRY): A Multicenter, Randomized Clinical Trial

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 306 (estimated)
• Sponsor: Qifu Li · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Using spironolactone as the control, to assess the efficacy and safety of finerenone in patients with primary aldosteronism(PA).

Detailed description

This is a multicenter, randomized study designed to evaluate efficacy and safety of finerenone in patients with PA. PA patients are randomly divided into two groups and treated with finerenone or spironolactone for 12 weeks. Spironolactone will be used as the control, while outcome will be assessed after 12-week treatment. Both drugs will be started at 20mg per day, Dose will be adjusted every four weeks to achieve the targeted blood pressure.

Conditions

• Primary Aldosteronism

Interventions

Type	Name	Description
DRUG	Finerenone Oral Tablet	Eligible patients will be started finerenone at 20mg per day, Dose will be adjusted every four weeks to achieve the targeted blood pressure (the mean office blood pressure \<140/90 mmHg).
DRUG	Spironolactone Oral Tablet	Eligible patients will be started spironolactone at 20mg per day, Dose will be adjusted every four weeks to achieve the targeted blood pressure (the mean office blood pressure \<140/90 mmHg).

Timeline

• Start date: 2024-06-04
• Primary completion: 2025-06-01
• Completion: 2026-06-01
• First posted: 2024-06-13
• Last updated: 2024-08-30

Locations

1 site across 1 country: China